Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer
- 1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA
- 2Winship Cancer Institute of Emory University, Atlanta, GA USA
- 3Institut Curie, Paris, France
Abstract
Background: The estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) treatment landscape continues to evolve with targeted therapy development. Estrogen receptor 1 (ESR1) testing is recommended at recurrence or each progression event to identify patients for effective therapies. However, there is limited information on testing and mutation patterns in the real world that can inform patient identification in the clinic.
Methods: A retrospective observational study among patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative MBC who initiated first line (1L) therapy with aromatase inhibitors or selective estrogen receptor degraders ± CDK4/6 inhibitors from 1 January, 2020 to 31 March, 2025, using the Flatiron Health Research Database was conducted. ESR1 testing and mutation positivity rates at 1L to third line initiation, stratified by endocrine-resistant, 1L endocrine-sensitive, and endocrine-sensitive/de novo MBC were descriptively reported.
Results: Overall testing rates varied across subgroups, with one or more ESR1 test per patient in 61.2% of patients with endocrine-resistant MBC (n = 2152), 50.5% in patients with 1L endocrine-sensitive MBC (n = 827), and 43.1% in patients with endocrine-sensitive/de novo MBC (n = 5772). Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups. ESR1 mutation positivity (ESR1m+) rates varied by subgroup at 1L initiation and were highest among patients with endocrine-resistant MBC (24.7%), followed by patients with 1L endocrine-sensitive MBC (6.9%) and patients with endocrine-sensitive/de novo MBC (2.1%). All groups had ESR1m+ rates around 30% at second line initiation and 40% at third line initiation. In an exploratory analysis, ~ 60% of ESR1 tests during 1L were conducted in tissue and ~ 40% in blood.
Conclusions: In this population, real-world ESR1 testing rates were low. One in four patients with endocrine-resistant MBC were ESR1m+ at 1L initiation, ~ 30% were ESR1m+ at second line across subgroups, and ~ 40% were ESR1m+ at third line across subgroups. More blood-based testing at recurrence and progression is recommended in the real world to align with guideline recommendations as ESR1m detection is more sensitive in blood than in tissue.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40291-026-00876-z.
Related
- 1076 Patient-derived organoids reveal tumor-restricted noncanonical HLA-I antigen candidates in low mutation burden metastatic melanoma
- Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment
- Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation
- Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
- Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
BibTeX
@article{liao2026bridging,
title = {{Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer}},
author = {Chi-Yin Liao and Jincy John and Precious Anyanwu and Manali A. Bhave and Francois-Clement Bidard and Tyler Marquart and Francisco Sapunar and Aarti Chawla and Lindsay A. Williams},
journal = {Molecular Diagnosis \& Therapy},
year = {2026},
month = sep,
doi = {10.1007/s40291-026-00876-z},
url = {https://doi.org/10.1007/s40291-026-00876-z},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer
AU - Chi-Yin Liao
AU - Jincy John
AU - Precious Anyanwu
AU - Manali A. Bhave
AU - Francois-Clement Bidard
AU - Tyler Marquart
AU - Francisco Sapunar
AU - Aarti Chawla
AU - Lindsay A. Williams
PY - 2026
DA - 2026/09/08
JO - Molecular Diagnosis & Therapy
DO - 10.1007/s40291-026-00876-z
UR - https://doi.org/10.1007/s40291-026-00876-z
AB - Background: The estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) treatment landscape continues to evolve with targeted therapy development. Estrogen receptor 1 (ESR1) testing is recommended at recurrence or each progression event to identify patients for effective therapies. However, there is limited information on testing and mutation patterns in the real world that can inform patient identification in the clinic. Methods: A retrospective observational study among patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative MBC who initiated first line (1L) therapy with aromatase inhibitors or selective estrogen receptor degraders ± CDK4/6 inhibitors from 1 January, 2020 to 31 March, 2025, using the Flatiron Health Research Database was conducted. ESR1 testing and mutation positivity rates at 1L to third line initiation, stratified by endocrine-resistant, 1L endocrine-sensitive, and endocrine-sensitive/de novo MBC were descriptively reported. Results: Overall testing rates varied across subgroups, with one or more ESR1 test per patient in 61.2% of patients with endocrine-resistant MBC (n = 2152), 50.5% in patients with 1L endocrine-sensitive MBC (n = 827), and 43.1% in patients with endocrine-sensitive/de novo MBC (n = 5772). Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups. ESR1 mutation positivity (ESR1m+) rates varied by subgroup at 1L initiation and were highest among patients with endocrine-resistant MBC (24.7%), followed by patients with 1L endocrine-sensitive MBC (6.9%) and patients with endocrine-sensitive/de novo MBC (2.1%). All groups had ESR1m+ rates around 30% at second line initiation and 40% at third line initiation. In an exploratory analysis, ~ 60% of ESR1 tests during 1L were conducted in tissue and ~ 40% in blood. Conclusions: In this population, real-world ESR1 testing rates were low. One in four patients with endocrine-resistant MBC were ESR1m+ at 1L initiation, ~ 30% were ESR1m+ at second line across subgroups, and ~ 40% were ESR1m+ at third line across subgroups. More blood-based testing at recurrence and progression is recommended in the real world to align with guideline recommendations as ESR1m detection is more sensitive in blood than in tissue. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40291-026-00876-z.
SN - 1177-1062
SN - 1179-2000
ER -